Clopidogrel Resistance in Stroke Patients From Different Ethnicities
- Conditions
- Ischemic StrokeClopidogrel, Poor Metabolism of
- Interventions
- Diagnostic Test: Quantification of platelet aggregation
- Registration Number
- NCT03806894
- Lead Sponsor
- Ziv Hospital
- Brief Summary
Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events. The aim of the present study is to evaluate the incidence of clopidogrel resistance in ischemic stroke patients from different ethnicities in Northern Israel and to find different strategies to overcome high platelet reactivity including clopidogrel dose adjustment or the choice of alternative agents. Quantification of platelet aggregation will be determined by vasodilator stimulated phosphoprotein (VASP) assay.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Ability to provide written informed consent and to be compliant with protocol assessments.
- Ages 18 and above inclusive
- Both genders eligible for the study
- Diagnosis of ischemic cerebrovascular event
Exclusion Criteria
- Pregnant patients will be excluded
- Ages below 18
- Patients not able to provide informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Arab populations Quantification of platelet aggregation Muslim, Christian, Druze Jewish communities Quantification of platelet aggregation Ashkenazi, Sephardi, Ethiopian
- Primary Outcome Measures
Name Time Method Rates of clopidogrel resistance assessed among the different ethnicities 6 months Identifying of high-risk subgroups of adverse clinical outcomes 6 to 12 months
- Secondary Outcome Measures
Name Time Method